Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Common Equity of $167.6 million for Q1 2026, up 95.52% year-over-year from $85.7 million in Q1 2025, and down 3.06% quarter-over-quarter from $172.9 million in Q4 2025.
Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Common Equity for 7 consecutive years, with $167.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 95.52% year-over-year to $167.6 million; the TTM figure through Mar 2026 stood at $167.6 million (up 95.52% YoY), while the FY2025 annual figure was $172.9 million, up 82.26% from the prior year.
- Common Equity retreated to $167.6 million in Q1 2026 per IKT's latest filing, from $172.9 million in the prior quarter.
- Across five years, Common Equity topped out at $172.9 million in Q4 2025 and bottomed at -$530591.0 in Q3 2024.
- Historically, Common Equity has averaged $50.9 million across 5 years, with a median of $25.3 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity sank 103.53% — and 2025, when it surged 13839.08%.
- Inhibikase Therapeutics' Common Equity stood at $21.0 million in 2022, then sank by 47.81% to $11.0 million in 2023, then soared by 764.16% to $94.9 million in 2024, then soared by 82.26% to $172.9 million in 2025, then declined by 3.06% to $167.6 million in 2026.
- Business Quant data shows IKT's Common Equity at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 153.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.33 Mn |
| Mar 31, 2026 | 167.62 Mn |
| Dec 31, 2025 | 172.90 Mn |
| Sep 30, 2025 | 72.90 Mn |
| Jun 30, 2025 | 80.05 Mn |
| Mar 31, 2025 | 85.73 Mn |
| Dec 31, 2024 | 94.87 Mn |
| Sep 30, 2024 | -530,591.00 |
| Jun 30, 2024 | 5.10 Mn |
| Mar 31, 2024 | 6.78 Mn |
| Dec 31, 2023 | 10.98 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 19.46 Mn |
| Mar 31, 2023 | 25.28 Mn |
| Dec 31, 2022 | 21.04 Mn |
| Sep 30, 2022 | 25.14 Mn |
| Jun 30, 2022 | 29.50 Mn |
| Mar 31, 2022 | 34.01 Mn |
| Dec 31, 2021 | 38.42 Mn |
| Sep 30, 2021 | 43.16 Mn |